skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

mti-UK-gov-orders-65-million

 

The UK government has signed a deal with Becton Dickinson & Co. to obtain 65 million injection devices to prepare for a COVID-19 vaccination program. The first shipments of the injection devices have already arrived in the UK, with the full order expected to be delivered by September 2020.

Due to the need to deploy future COVID-19 vaccinations quickly, they are expected to be made available initially in single or multidose vials. This requires the use of separate needles and syringes to draw the vaccine from the vial and administer it to patients.

"BD’s dose-sparing injection devices are engineered to increase the available amount of vaccine by minimizing vaccine waste. These devices can also play an essential role in expanding available vaccine doses during a pandemic. The savings associated with lower vaccine waste are greater than the total cost of dose-sparing injection devices," BD UK&I general manager, Mike Fairbourn told Medtech Insight.

BD is the largest manufacturer of injection devices in the world. In June, the company secured its first deal with the Canadian government to supply 37 million injection devices for COVID-19 vaccines. According to Fairbourn, the company is in discussions with the US and multiple other governments around the world to supply more of the devices.

"The UK selected a device that was able to be produced and delivered in a very rapid timeframe to ensure they are prepared for whenever a vaccine is prepared," said Fairbourn. "We aren’t vaccine manufacturers, so we won’t speculate on timing, but widely published reports show a vaccine is expected late in 2020 or early in 2021."

Fairbourn said the deal is not material to BD from a financial perspective.

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now